tiprankstipranks
Trending News
More News >
Soligenix Inc (SNGX)
:SNGX

Soligenix (SNGX) AI Stock Analysis

Compare
662 Followers

Top Page

SN

Soligenix

(NASDAQ:SNGX)

Rating:39Underperform
Price Target:
Soligenix's overall stock score is primarily driven by its weak financial performance, characterized by declining revenues and persistent losses. While the technical analysis indicates some potential for short-term stability, the valuation and financial metrics suggest ongoing challenges. The company's recent loan repayment is a positive step towards financial flexibility, but it does not alleviate the underlying financial and operational issues.

Soligenix (SNGX) vs. SPDR S&P 500 ETF (SPY)

Soligenix Business Overview & Revenue Model

Company DescriptionSoligenix, Inc. (SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company's core sectors include biotherapeutics and public health solutions. Within biotherapeutics, it is engaged in the development of specialized drug products for oncology, inflammation, and biodefense. Soligenix's lead product candidates include SGX301, a novel photodynamic therapy for cutaneous T-cell lymphoma, and SGX942, an innate defense regulator for the treatment of oral mucositis in head and neck cancer patients.
How the Company Makes MoneySoligenix makes money primarily through the research, development, and commercialization of its biopharmaceutical products. The company's revenue streams include government grants and contracts, especially for its biodefense programs, as well as potential future revenues from product sales, partnerships, and collaborations with other pharmaceutical companies. Soligenix's financial success is heavily dependent on the successful development and approval of its lead product candidates, which can result in licensing agreements, milestone payments, and royalties. Additionally, its biodefense division benefits from government funding, which supports the development of vaccines and therapeutics for potential bioterrorism threats.

Soligenix Financial Statement Overview

Summary
Soligenix's financial health is concerning, with significant revenue decline, ongoing net losses, and high reliance on external financing. The company faces operational inefficiencies, evident in its negative margins and cash flow challenges. Despite efforts to secure financing, sustainability remains questionable without improvements in revenue and profitability.
Income Statement
25
Negative
Soligenix has experienced significant revenue decline over recent years, with a sharp drop from $4.6M in 2019 to just $119k in 2024. The net profit margin remains deeply negative, with a net loss of $8.7M in 2024. Both EBIT and EBITDA margins are negative, indicating ongoing operational challenges and inefficiencies in cost management. Revenue growth has also been inconsistent, reflecting volatility in business operations.
Balance Sheet
30
Negative
The company's balance sheet shows high financial leverage, with a debt-to-equity ratio fluctuating due to negative equity in some years. In 2024, the equity ratio improved slightly but still indicates reliance on debt financing. Return on equity remains negative due to continued net losses. Total assets have decreased significantly since 2019, reflecting a reduction in company scale and potentially diminishing asset utility.
Cash Flow
40
Negative
Soligenix's cash flow statements highlight consistent negative operating cash flow, indicating challenges in generating cash from core operations. Despite this, financing activities have periodically provided cash infusions, such as in 2024 with $7.7M from financing. Free cash flow remains negative, suggesting persistent cash outflows exceeding cash inflows from operations and investments.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue119.37K839.36K948.91K824.27K2.36M
Gross Profit-125.00K97.31K398.09K95.63K538.50K
EBITDA-8.64M-7.85M-14.11M-12.48M-18.45M
Net Income-8.68M-6.14M-13.80M-12.55M-17.69M
Balance Sheet
Total Assets8.97M9.80M14.28M26.87M19.89M
Cash, Cash Equivalents and Short-Term Investments7.82M8.45M13.36M26.04M18.68M
Total Debt1.48M3.49M10.24M9.96M10.51M
Total Liabilities4.85M7.27M16.75M16.15M16.15M
Stockholders Equity4.12M2.52M-2.47M10.72M3.74M
Cash Flow
Free Cash Flow-8.40M-8.60M-12.66M-11.75M-11.46M
Operating Cash Flow-8.40M-8.60M-12.65M-11.74M-11.45M
Investing Cash Flow0.000.00-13.07K-11.79K-7.15K
Financing Cash Flow7.76M3.66M76.82K19.06M24.68M

Soligenix Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.26
Price Trends
50DMA
1.83
Negative
100DMA
2.03
Negative
200DMA
2.68
Negative
Market Momentum
MACD
-0.16
Positive
RSI
26.30
Positive
STOCH
13.93
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNGX, the sentiment is Negative. The current price of 1.26 is below the 20-day moving average (MA) of 1.65, below the 50-day MA of 1.83, and below the 200-day MA of 2.68, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 26.30 is Positive, neither overbought nor oversold. The STOCH value of 13.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNGX.

Soligenix Risk Analysis

Soligenix disclosed 47 risk factors in its most recent earnings report. Soligenix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Soligenix Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
49
Neutral
AU$2.48B4.33-64.25%2.85%36.51%13.14%
48
Neutral
$11.68M-655.00%-26.38%40.99%
42
Neutral
$7.06M-233.67%-1786.46%
39
Underperform
$4.60M-437.73%57.83%
34
Underperform
$6.97M-590.37%-73095.97%
33
Underperform
$12.73M-339.64%-75.88%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SNGX
Soligenix
1.26
-0.85
-40.28%
EVGN
Evogene
1.36
-5.00
-78.62%
MTVA
MetaVia
0.66
-3.87
-85.43%
SLXN
Silexion Therapeutics
0.80
-105.62
-99.25%
APLM
Apollomics
6.56
-12.56
-65.69%

Soligenix Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Soligenix Repays Loan, Boosting Financial Flexibility
Positive
Feb 10, 2025

On February 5, 2025, Soligenix, Inc. fully repaid and terminated its Loan and Security Agreement with Pontifax Medison Finance, eliminating all outstanding obligations and associated liens without incurring any prepayment penalties. This move reflects the company’s financial stability and strengthens its operational flexibility, potentially enhancing its position in the biopharmaceutical industry.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025